MRNA looking strong at cmp

Moderna remains in a precarious transition phase—from COVID-revenue dependency toward a diversified vaccine portfolio. Technically, momentum favors upside in the short-term, but fundamentals and macro-regulatory factors suggest caution. If its RSV and flu/COVID combo rollouts succeed and regulatory support stabilizes, it could rebound toward analyst targets near 60. Otherwise, expect choppier consolidation or downward pressure.